Accelerated Approval: Avastin, Makena Bookend A Watershed Decade For US FDA’s Expedited Pathway

28 Apr 2020

Pink Sheet interactive timeline looks at key regulatory, policy and legislative developments impacting the accelerated approval pathway over the last 10 years.

Vintage books enclosed by old fashioned bookends with a moody dark background — Avastin and Makena became bookends for US FDA's accelerated approval program in the last decade. • Source: Shutterstock

Accelerated Approval: Avastin, Makena Bookend A Watershed Decade For US FDA’s Expedited Pathway

More from Review Pathways

More from Pathways & Standards